|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000198930 |
Summary for CSAG1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000198930 | Gene symbol | CSAG1 |
| Gene name | chondrosarcoma associated gene 1 | |
| HGNC | 24294 | |
| Entrez ID | 158511 | |
| Gene type | protein_coding | |
| Synonyms | CSAG1|CSAGE|CT24.1 | |
| UniProtAcc | Q6PB30 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for CSAG1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CSAG1 | 1.85e+02 | 1.25e+00 | 3.53e-01 | 3.53e+00 | 4.10e-04 | 5.56e-03 | LUAD |
| CSAG1 | 2.21e+01 | 2.67e+00 | 2.53e-01 | 1.06e+01 | 4.50e-26 | 3.39e-23 | THCA |
| CSAG1 | 5.69e+01 | -1.29e+00 | 4.43e-01 | -2.91e+00 | 3.62e-03 | 2.18e-02 | SARC |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CSAG1 | 3.90e+02 | 8.13e+00 | 1.19e+00 | 6.83e+00 | 8.46e-12 | 2.36e-10 | BLCA |
| CSAG1 | 4.69e+00 | 3.34e+00 | 8.87e-01 | 3.77e+00 | 1.66e-04 | 5.17e-04 | KICH |
| CSAG1 | 2.90e+02 | 4.26e+00 | 1.26e+00 | 3.37e+00 | 7.38e-04 | 4.95e-03 | ESCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CSAG1 | 1.83e+01 | 6.74e+00 | 1.14e+00 | 5.92e+00 | 3.22e-09 | 1.58e-08 | COAD |
| CSAG1 | 4.29e+01 | 8.26e+00 | 4.40e-01 | 1.88e+01 | 1.10e-78 | 2.47e-77 | BRCA |
| CSAG1 | 1.71e+01 | 5.87e+00 | 1.64e+00 | 3.57e+00 | 3.56e-04 | 1.43e-03 | READ |
Top |
Sex-biased somatic mutation for CSAG1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for CSAG1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg00157034 | chrX:152733210 | CGI:chrX:152698699-152698991 | UTR,promoter,exon,gene body | 6.47e-01 | 4.61e-01 | 2.41e+00 | 1.61e-02 | 3.22e-02 | 1.86e-01 |
| LGG | cg08341323 | chrX:152733744 | CGI:chrX:152698699-152698991 | promoter | 7.67e-01 | 8.69e-01 | -1.55e+01 | 1.86e-54 | 2.16e-53 | -1.02e-01 |
| LGG | cg09141697 | chrX:152733738 | CGI:chrX:152698699-152698991 | promoter | 7.63e-01 | 8.74e-01 | -1.43e+01 | 1.11e-46 | 1.13e-45 | -1.11e-01 |
| KIRP | cg09141697 | chrX:152733738 | CGI:chrX:152698699-152698991 | promoter | 7.75e-01 | 8.85e-01 | -8.72e+00 | 2.83e-18 | 4.76e-17 | -1.10e-01 |
| PCPG | cg05101765 | chrX:152734519 | CGI:chrX:152769491-152769783 | promoter | 7.20e-01 | 8.42e-01 | -9.37e+00 | 7.46e-21 | 7.55e-20 | -1.22e-01 |
| PCPG | cg09141697 | chrX:152733738 | CGI:chrX:152698699-152698991 | promoter | 6.61e-01 | 7.62e-01 | -5.38e+00 | 7.44e-08 | 3.71e-07 | -1.01e-01 |
| CHOL | cg09141697 | chrX:152733738 | CGI:chrX:152698699-152698991 | promoter | 6.75e-01 | 8.05e-01 | -2.71e+00 | 6.81e-03 | 1.64e-02 | -1.30e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUSC | cg05101765 | chrX:152734519 | CGI:chrX:152769491-152769783 | promoter | 7.54e-01 | 8.54e-01 | -3.44e+00 | 5.75e-04 | 1.81e-03 | -1.00e-01 |
| LUSC | cg08341323 | chrX:152733744 | CGI:chrX:152698699-152698991 | promoter | 6.45e-01 | 8.38e-01 | -3.67e+00 | 2.43e-04 | 1.08e-03 | -1.93e-01 |
| LUSC | cg09141697 | chrX:152733738 | CGI:chrX:152698699-152698991 | promoter | 5.95e-01 | 8.46e-01 | -3.74e+00 | 1.88e-04 | 9.38e-04 | -2.50e-01 |
| LUSC | cg00157034 | chrX:152733210 | CGI:chrX:152698699-152698991 | UTR,promoter,exon,gene body | 6.97e-01 | 9.16e-01 | -3.58e+00 | 3.50e-04 | 1.33e-03 | -2.19e-01 |
| ESCA | cg05101765 | chrX:152734519 | CGI:chrX:152769491-152769783 | promoter | 7.49e-01 | 8.52e-01 | -2.47e+00 | 1.34e-02 | 3.76e-02 | -1.03e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg05101765 | chrX:152734519 | CGI:chrX:152769491-152769783 | promoter | 6.96e-01 | 8.11e-01 | -9.08e+00 | 1.13e-19 | 5.96e-19 | -1.15e-01 |
| BRCA | cg08341323 | chrX:152733744 | CGI:chrX:152698699-152698991 | promoter | 5.99e-01 | 7.42e-01 | -9.74e+00 | 1.96e-22 | 1.31e-21 | -1.43e-01 |
| BRCA | cg09141697 | chrX:152733738 | CGI:chrX:152698699-152698991 | promoter | 5.87e-01 | 7.69e-01 | -9.69e+00 | 3.21e-22 | 2.11e-21 | -1.81e-01 |
| BRCA | cg00157034 | chrX:152733210 | CGI:chrX:152698699-152698991 | UTR,promoter,exon,gene body | 6.47e-01 | 8.61e-01 | -1.00e+01 | 1.55e-23 | 1.15e-22 | -2.14e-01 |
Top |
Exon skipping events with PSI in TCGA for CSAG1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for CSAG1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for CSAG1 |
| TFs related to CSAG1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | PLAGL2 | CSAG1 | 4.13e+00 | 9.86e-01 | 1.93e+00 | 5.24e-04 | Male-biased |
| BRCA | ZNF264 | CSAG1 | 4.15e+00 | 9.84e-01 | 2.52e+00 | 2.95e-03 | Male-biased |
| DLBC | KLF10 | CSAG1 | 3.08e+00 | 3.54e-03 | 4.25e+00 | 9.87e-01 | Female-biased |
| DLBC | KLF17 | CSAG1 | 3.11e+00 | 3.67e-03 | 4.27e+00 | 9.87e-01 | Female-biased |
| DLBC | NFKB2 | CSAG1 | 3.77e+00 | 8.97e-03 | 4.70e+00 | 9.86e-01 | Female-biased |
| DLBC | PLAGL2 | CSAG1 | 3.21e+00 | 1.02e-03 | 4.76e+00 | 9.95e-01 | Female-biased |
| DLBC | SALL4 | CSAG1 | 2.89e+00 | 4.58e-03 | 3.99e+00 | 9.80e-01 | Female-biased |
| DLBC | TP73 | CSAG1 | 3.43e+00 | 1.03e-02 | 4.32e+00 | 9.81e-01 | Female-biased |
| DLBC | XPA | CSAG1 | 3.57e+00 | 1.07e-02 | 4.44e+00 | 9.82e-01 | Female-biased |
| DLBC | ZBTB12 | CSAG1 | 3.50e+00 | 5.43e-03 | 4.57e+00 | 9.89e-01 | Female-biased |
| DLBC | ZFX | CSAG1 | 2.92e+00 | 1.38e-03 | 4.37e+00 | 9.91e-01 | Female-biased |
| DLBC | ZIC2 | CSAG1 | 2.99e+00 | 1.77e-03 | 4.37e+00 | 9.90e-01 | Female-biased |
| DLBC | ZIC3 | CSAG1 | 3.09e+00 | 3.57e-03 | 4.26e+00 | 9.87e-01 | Female-biased |
| DLBC | ZIC4 | CSAG1 | 3.39e+00 | 4.91e-03 | 4.48e+00 | 9.88e-01 | Female-biased |
| DLBC | ZIC5 | CSAG1 | 3.32e+00 | 5.62e-03 | 4.37e+00 | 9.86e-01 | Female-biased |
| DLBC | ZNF264 | CSAG1 | 3.42e+00 | 2.47e-03 | 4.71e+00 | 9.93e-01 | Female-biased |
| DLBC | ZNF300 | CSAG1 | 3.19e+00 | 3.33e-03 | 4.38e+00 | 9.89e-01 | Female-biased |
| DLBC | ZNF343 | CSAG1 | 3.59e+00 | 9.62e-03 | 4.49e+00 | 9.84e-01 | Female-biased |
| DLBC | ZNF530 | CSAG1 | 3.19e+00 | 4.72e-03 | 4.29e+00 | 9.86e-01 | Female-biased |
| DLBC | ZNF573 | CSAG1 | 3.38e+00 | 5.78e-03 | 4.43e+00 | 9.87e-01 | Female-biased |
| DLBC | ZNF765 | CSAG1 | 3.17e+00 | 2.80e-03 | 4.42e+00 | 9.90e-01 | Female-biased |
| DLBC | ZNF768 | CSAG1 | 3.05e+00 | 4.80e-03 | 4.14e+00 | 9.83e-01 | Female-biased |
| ESCA | FEV | CSAG1 | 5.23e+00 | 9.92e-01 | 4.42e+00 | 6.16e-03 | Male-biased |
| PCPG | NFKB2 | CSAG1 | 3.89e+00 | 1.13e-02 | 4.67e+00 | 9.84e-01 | Female-biased |
| PCPG | PLAGL2 | CSAG1 | 3.23e+00 | 1.15e-03 | 4.50e+00 | 9.93e-01 | Female-biased |
| PCPG | ZBTB12 | CSAG1 | 3.70e+00 | 1.18e-02 | 4.47e+00 | 9.82e-01 | Female-biased |
| PCPG | ZFX | CSAG1 | 3.10e+00 | 4.81e-03 | 4.06e+00 | 9.83e-01 | Female-biased |
| PCPG | ZIC2 | CSAG1 | 2.92e+00 | 2.84e-03 | 3.99e+00 | 9.83e-01 | Female-biased |
| PCPG | ZNF264 | CSAG1 | 3.59e+00 | 9.29e-03 | 4.41e+00 | 9.84e-01 | Female-biased |
| PCPG | ZNF300 | CSAG1 | 2.90e+00 | 3.22e-03 | 3.95e+00 | 9.82e-01 | Female-biased |
| PCPG | ZNF530 | CSAG1 | 3.04e+00 | 4.41e-03 | 4.02e+00 | 9.82e-01 | Female-biased |
| SARC | MBD2 | CSAG1 | 4.51e+00 | 9.90e-01 | 3.73e+00 | 2.61e-03 | Male-biased |
| SARC | PLAGL2 | CSAG1 | 4.92e+00 | 9.90e-01 | 4.29e+00 | 6.61e-03 | Male-biased |
| SARC | ZBTB26 | CSAG1 | 4.06e+00 | 9.81e-01 | 3.38e+00 | 4.52e-03 | Male-biased |
| SARC | ZIC4 | CSAG1 | 4.52e+00 | 9.82e-01 | 3.98e+00 | 1.10e-02 | Male-biased |
| SARC | ZNF300 | CSAG1 | 4.44e+00 | 9.85e-01 | 3.83e+00 | 7.13e-03 | Male-biased |
| CSAG1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for CSAG1 |
| RBPs related to ES in CSAG1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CSAG1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000198930 |
| CpG Site: cg00157034 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: -0.263218278143349 | |
| Female Effect: - | |
 | Gene ID: ENSG00000198930 |
| CpG Site: cg09141697 | |
| Position to Gene: promoter | |
| Male Effect: -0.22168618465123 | |
| Female Effect: - | |
 | Gene ID: ENSG00000198930 |
| CpG Site: cg00157034 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: -0.164323935001641 | |
| Female Effect: - | |
 | Gene ID: ENSG00000198930 |
| CpG Site: cg08341323 | |
| Position to Gene: promoter | |
| Male Effect: -0.231268769647049 | |
| Female Effect: - | |
 | Gene ID: ENSG00000198930 |
| CpG Site: cg05101765 | |
| Position to Gene: promoter | |
| Male Effect: -0.314634241754381 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg00157034 | chrX:152733210 | gene,exon,promoter,UTR | -0.263218278143349 | 3.62308822887614e-06 | -0.37413559065420193 | 9.455472486192562e-09 | LUAD |
| cg09141697 | chrX:152733738 | promoter | -0.22168618465123 | 8.05917137100305e-17 | -0.48899270334991557 | 1.114580603046813e-19 | BLCA |
| cg00157034 | chrX:152733210 | gene,exon,promoter,UTR | -0.164323935001641 | 5.17406562762722e-13 | -0.4387261350629275 | 9.855498982349096e-16 | BLCA |
| cg08341323 | chrX:152733744 | promoter | -0.231268769647049 | 2.68435801552462e-11 | -0.41621509975086185 | 3.298962749192386e-14 | BLCA |
| cg05101765 | chrX:152734519 | promoter | -0.314634241754381 | 8.68070488560667e-07 | -0.3235327973919804 | 7.323230909068301e-09 | BLCA |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of CSAG1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
